"Drug Precision" is a series of live broadcast columns jointly launched by Genetronics and the Translational Medicine Network, "Focus on Drug Targets, Precision Accompanying". Precision medicine, diagnosis first, supports the high-quality research and development of innovative drugs .
Issue 10
fusion gene is a type of mutation that is very important in driving tumor development. Fusion mutations are distributed in almost all cancer types. To date, more than 10,000 cancer-related fusion gene mutations [1] have been discovered. Tumor fusion gene mutations not only play an important guiding role in the diagnosis and prognosis process, but also gradually become an effective target for targeted drug development.[2]. The FDA or NMPA has approved a number of corresponding targeted drugs for fusion targets such as ALK, ROS1, RET, FGFR2 and NTRK1/2/3. There are many detection methods for fusion genes. How to choose the most appropriate method for accurate detection of fusion genes in drug development and clinical practice?
In this live broadcast of "Drug Precision", Dr. Yao Sheng, clinical scientific director of Cornerstone Pharmaceuticals, Dr. Song Zhengbo, of the University Cancer Hospital of the Chinese Academy of Sciences, and Ma Tonghui, director of the Department of Translational Medicine at Genetronics, will work together to discuss new advances in tumor fusion gene-targeted drugs and detection technologies.
In addition, in order to better understand everyone's points of interest, improve the relevance of experts' live broadcasts, and promptly answer questions raised by users, we have also opened a communication group. If you are interested in the "Drug Accuracy" series of live broadcasts, you are welcome to join the group to exchange ideas, discuss issues, watch live broadcasts + reviews with practitioners in the biomedical industry, and have multiple gifts! Welcome to add staff on WeChat and invite you to join the group. Please note " name + unit + department "!
column introduction
References:
1. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (2017). MitelmanF, Johansson B and MertensF (Eds.), http://cgap.nci.nih.gov/Chromosomes/Mitelman.
2. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Chandan Kumar-Sinha, Shanker Kalyana-Sundaram, Arul M.Chinnaiyan. Genome Med. 2015; 7: 129.
END
